Compass Therapeutics, Inc. (CMPX)
0.86
-0.04
(-4.09%)
USD |
NASDAQ |
Oct 16, 16:00
0.8637
0.00 (0.00%)
After-Hours: 20:00
Compass Therapeutics Research and Development Expense (Annual) : 55.69M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 55.69M |
| December 31, 2024 | 41.75M |
| December 31, 2023 | 37.42M |
| December 31, 2022 | 29.22M |
| Date | Value |
|---|---|
| December 31, 2021 | 19.77M |
| December 31, 2020 | 14.90M |
| December 31, 2019 | 22.45M |
| December 31, 2018 | 27.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Viking Therapeutics, Inc. | 344.96M |
| Capricor Therapeutics, Inc. | 83.50M |
| Ardelyx, Inc. | 68.47M |
| Biomea Fusion, Inc. | 61.98M |
| ARS Pharmaceuticals, Inc. | 13.18M |